Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL754557 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL30388817 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL19148648 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 1.00 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1130036 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1402209 | 0.99 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302880-A1 | PLATELET DERIVATIVE COMPOSITIONS IN THE FORM OF A POWDER | CELLPHIRE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12419914-B2 | Thrombosomes as an antiplatelet agent reversal agent | CELLPHIRE, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12370219-B2 | Platelet derivative compositions, and pluralities of containers containing same | CELLPHIRE, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250205284-A1 | PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAME | CELLPHIRE, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250177450-A1 | METHODS FOR ADMINISTERING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS TO SUBJECTS TREATED WITH A FACTOR XI INHIBITOR | CELLPHIRE, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-12295972-B2 | Methods using freeze-dried platelet derivative compositions for restoring hemostasis in a subject | CELLPHIRE, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119798022-A | Method for splitting clopidogrel and camphorsulfonic acid | 惠州信立泰药业有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12208122-B2 | Methods of treating bleeding in a subject treated with an antiplatelet agent | CELLPHIRE, INC (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240408141-A1 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING A SUBJECT TAKING AN ANTI-PLATELET AGENT | CELLPHIRE, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240277771-A1 | METHODS OF TREATING BLEEDING IN A SUBJECT TREATED WITH AN ANTIPLATELET AGENT | CELLPHIRE, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-7470707-B2 | Crystalline monohydrate clopidogrel naphthalenedisulfonate and process of preparation | HANMI PHARM. CO., LTD (KR) | 2008-12-30 | — | — | US | disclosed |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2008-10-09 | — | — | US | disclosed |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2008-10-09 | — | — | US | disclosed |
| US-20080182869-A1 | Method of Racemization of the R(-) Isomer of the (2-Chlorophenyl)-6,7-Dihydrothieno[3,2-C]Pyridine-5(4H)-Acetic Acid Methyl Ester | ZENTIVA K.S. (CZ) | 2008-07-31 | — | — | US | disclosed |
| US-20080182869-A1 | Method of Racemization of the R(-) Isomer of the (2-Chlorophenyl)-6,7-Dihydrothieno[3,2-C]Pyridine-5(4H)-Acetic Acid Methyl Ester | ZENTIVA K.S. (CZ) | 2008-07-31 | — | — | US | disclosed |
| WO-2008081473-A2 | PROCESS FOR PREPARING CLOPIDOGREL | CADILA HEALTHCARE LIMITED (IN) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008062421-A1 | A PROCESS FOR PREPARING (S)-(+)-CLOPIDOGREL BASE AND ITS SALTS | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | DR. REDDY'S LABORATORIES, INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1606231-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | Nadkarni, Sunil Sadanand (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004074215-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | NADKARNI SUNIL SADANAND (IN) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182869-A1 | Method of Racemization of the R(-) Isomer of the (2-Chlorophenyl)-6,7-Dihydrothieno[3,2-C]Pyridine-5(4H)-Acetic Acid Methyl Ester | HRH2, HTR3E, ADRA2C | P2RY12 168/4885ABCB11 867/4885OPRM1 49/4885 |
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | PFKP, SELP, P2RY13 | P2RY12 7/4885ABCB11 200/4885OPRM1 3881/4885 |
| US-20080249311-A1 | Using halogen phenyl acetonitrile as starting material; tetrahydrothienopyridine (acetate or acetonitrile) as chemical intermediates; kinetic resolution; anticoagulant | TFPI, F2, CYP2C19 | P2RY12 20/4885ABCB11 539/4885OPRM1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.